Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib

被引:45
作者
Li, Yong-Tao [1 ,2 ,3 ]
Wang, Jing-Han [1 ,2 ,3 ]
Pan, Cheng-Wen [1 ,2 ,3 ]
Meng, Fan-Fei [1 ,2 ,3 ]
Chu, Xiao-Qian [3 ]
Ding, Ya-hui [1 ,2 ]
Qua, Wen-Zheng [1 ,2 ,3 ]
Li, Hui-ying [3 ]
Yang, Cheng [1 ,2 ,3 ]
Zhang, Quan [1 ,2 ]
Bai, Cui-Gai [3 ]
Chen, Yue [1 ,2 ]
机构
[1] Nankai Univ, Coll Pharm, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, State Key Lab Elementoorgan Chem, Tianjin 300071, Peoples R China
[2] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300071, Peoples R China
[3] Tianjin Int Joint Acad BioMed, High Throughput Mol Drug Discovery Ctr, Tianjin 300457, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic myelogenous leukemia; K562; KG-1a; Imatinib; Synthesis; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; CANCER STEM-CELLS; BCR-ABL; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; MEDICINAL CHEMISTRY; INHIBITORS; RESISTANCE; BIOISOSTERISM;
D O I
10.1016/j.bmcl.2016.01.068
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Three novel series of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib were prepared and evaluated in vitro for their cytostatic effects against a human chronic myeloid leukemia (K562), acute myeloid leukemia (HL60), and human leukemia stem-like cell line (KG1a). The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analog. Benzene and piperazine rings were necessary groups in these compounds for maintaining inhibitory activities against the K562 and HL60 cell lines. Introducing a trifluoromethyl group significantly enhanced the potency of the compounds against these two cell lines. Surprisingly, some compounds showed significant inhibitory activities against KG1a cells without inhibiting common leukemia cell lines (K562 and HL60). These findings suggest that these compounds are able to inhibit leukemia stem-like cells. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1419 / 1427
页数:9
相关论文
共 38 条
[1]
N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a Scaffold for the Synthesis of Inhibitors of Bcr-Abl [J].
Arioli, Federica ;
Borrelli, Stella ;
Colombo, Francesco ;
Falchi, Federico ;
Filippi, Irene ;
Crespan, Emmanuele ;
Naldini, Antonella ;
Scalia, Giusy ;
Silvani, Alessandra ;
Maga, Giovanni ;
Carraro, Fabio ;
Botta, Maurizio ;
Passarella, Daniele .
CHEMMEDCHEM, 2011, 6 (11) :2009-2018
[2]
Oxadiazoles in Medicinal Chemistry [J].
Bostrom, Jonas ;
Hogner, Anders ;
Llinas, Antonio ;
Wellner, Eric ;
Plowright, Alleyn T. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) :1817-1830
[3]
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer [J].
Carmi, Caterina ;
Mor, Marco ;
Petronini, Pier Giorgio ;
Alfieri, Roberta R. .
BIOCHEMICAL PHARMACOLOGY, 2012, 84 (11) :1388-1399
[4]
The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It? [J].
Carter, Bing Z. ;
Mak, Duncan H. ;
Cortes, Jorge ;
Andreeff, Michael .
SEMINARS IN HEMATOLOGY, 2010, 47 (04) :362-370
[5]
Amide-1,2,3-triazole bioisosterism: the glycogen phosphorylase case [J].
Chrysina, Evangelia D. ;
Bokor, Eva ;
Alexacou, Kyra-Melinda ;
Charavgi, Maria-Despoina ;
Oikonomakos, George N. ;
Zographos, Spyros E. ;
Leonidas, Demetres D. ;
Oikonomakos, Nikos G. ;
Laszlo, Somsak .
TETRAHEDRON-ASYMMETRY, 2009, 20 (6-8) :733-740
[6]
Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients [J].
Ciarcia, Roberto ;
Vitiello, Maria Teresa ;
Galdiero, Massimiliano ;
Pacilio, Carmen ;
Iovane, Valentina ;
D'Angelo, Danila ;
Pagnini, David ;
Caparrotti, Giuseppe ;
Conti, Daniele ;
Tomei, Valentina ;
Florio, Salvatore ;
Giordano, Antonio .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (06) :2798-2803
[7]
The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].
Deininger, M ;
Buchdunger, E ;
Druker, BJ .
BLOOD, 2005, 105 (07) :2640-2653
[8]
Broad spectrum alkynyl inhibitors of T315I Bcr-Abl [J].
Deng, Xianming ;
Lim, Sang Min ;
Zhang, Jianming ;
Gray, Nathanael S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) :4196-4200
[9]
hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications [J].
Deville, Laure ;
Hillion, Josette ;
Pendino, Frederic ;
Samy, Mona ;
Nguyen, Eric ;
Segal-Bendirdjian, Evelyne .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (05) :711-719
[10]
Translation of the Philadelphia chromosome into therapy for CML [J].
Druker, Brian J. .
BLOOD, 2008, 112 (13) :4808-4817